Cargando…

Functional Antibodies in COVID-19 Convalescent Plasma

In the absence of an effective vaccine or monoclonal therapeutic, transfer of convalescent plasma (CCP) was proposed early in the SARS-CoV-2 pandemic as an easily accessible therapy. However, despite the global excitement around this historically valuable therapeutic approach, results from CCP trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herman, Jonathan D., Wang, Chuangqi, Loos, Carolin, Yoon, Hyunah, Rivera, Johanna, Dieterle, M. Eugenia, Haslwanter, Denise, Jangra, Rohit K., Bortz, Robert H., Bar, Katharine J., Julg, Boris, Chandran, Kartik, Lauffenburger, Douglas, Pirofski, Liise-anne, Alter, Galit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987034/ https://www.ncbi.nlm.nih.gov/pubmed/33758875 http://dx.doi.org/10.1101/2021.03.08.21253157

Ejemplares similares

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
por: Herman, Jonathan D., et al.
Publicado: (2021)

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
por: Herman, Jonathan D., et al.
Publicado: (2022)

COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic
por: Pirofski, Liise-anne
Publicado: (2023)

Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023)

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
por: Dieterle, M. Eugenia, et al.
Publicado: (2020)

A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition
por: Dieterle, M. Eugenia, et al.
Publicado: (2020)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2020)

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
por: Yoon, Hyun ah, et al.
Publicado: (2021)

Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
por: Bartsch, Yannic C., et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

A Glycoprotein Mutation That Emerged during the 2013–2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion
por: Fels, J. Maximilian, et al.
Publicado: (2021)

Cryptococcus neoformans–Specific and Non–Cryptococcus neoformans–Specific Antibody Profiles in Organ Transplant Recipients With and Without Cryptococcosis
por: Yoon, Hyunah, et al.
Publicado: (2022)

Genetic depletion studies inform receptor usage by virulent hantaviruses in human endothelial cells
por: Dieterle, Maria Eugenia, et al.
Publicado: (2021)

Two Point Mutations in Old World Hantavirus Glycoproteins Afford the Generation of Highly Infectious Recombinant Vesicular Stomatitis Virus Vectors
por: Slough, Megan M., et al.
Publicado: (2019)

Genomic surveillance of SARS-CoV-2 during the first year of the pandemic in the Bronx enabled clinical and epidemiological inference
por: Fels, J. Maximilian, et al.
Publicado: (2022)

Genomic surveillance of SARS-CoV-2 during the first year of the pandemic in the Bronx enabled clinical and epidemiological inference
por: Fels, J. Maximilian, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Cryptococcal Antigen Screening and Missed Opportunities for Earlier Diagnosis Among People With HIV and Poor Virologic Control in the Bronx, NY
por: Yoon, Hyunah, et al.
Publicado: (2022)

Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation
por: Mittler, Eva, et al.
Publicado: (2021)

Virulence profile: Liise-anne Pirofski
por: Pirofski, Liise-anne
Publicado: (2017)

Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic
por: Pirofski, Liise-anne
Publicado: (2021)

Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis
por: Herrera, Natalia G., et al.
Publicado: (2020)

Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis
por: Herrera, Natalia G., et al.
Publicado: (2020)

Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
por: Loos, Carolin, et al.
Publicado: (2020)

Naïve B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1(−/−) mice
por: Dufaud, Chad, et al.
Publicado: (2017)

Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
por: Muena, Nicolás A., et al.
Publicado: (2021)

Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway
por: Spence, Jennifer S., et al.
Publicado: (2016)

Exploiting the Redundancy in the Immune System: Vaccines Can Mediate Protection by Eliciting ‘Unnatural’ Immunity
por: Casadevall, Arturo, et al.
Publicado: (2003)

Rethinking T cell immunity in oropharyngeal candidiasis
por: Pirofski, Liise-anne, et al.
Publicado: (2009)

Q and A What is a pathogen? A question that begs the point
por: Pirofski, Liise-anne, et al.
Publicado: (2012)

The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
por: Casadevall, Arturo, et al.
Publicado: (2015)

What is infectiveness and how is it involved in infection and immunity?
por: Pirofski, Liise-anne, et al.
Publicado: (2015)

Immune-Mediated Damage Completes the Parabola: Cryptococcus neoformans Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response
por: Pirofski, Liise-anne, et al.
Publicado: (2017)

The Damage–Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases
por: Pirofski, Liise-anne, et al.
Publicado: (2018)

647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
por: Babb, Rachelle, et al.
Publicado: (2018)

Benefits and Costs of Animal Virulence for Microbes
por: Casadevall, Arturo, et al.
Publicado: (2019)

Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework
por: Pirofski, Liise-anne, et al.
Publicado: (2020)

Immunomodulators as an antimicrobial tool
por: Pirofski, Liise-anne, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_snjdaa1nd4d2mop8ls1k8n8874